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1 Background
1.1. Overview of hepatitis C virus
Hepatitis C virus (HCV) is a major cause of liver disease worldwide. Globally, it is estimated that there are 
115 million people who have had HCV infection, and 80 million with chronic infection (1).
Transmission of HCV occurs through contact with the blood of an infected person. Risk factors for HCV 
differ globally. In developed countries like Ireland, injecting drug use (IDU) is the major risk factor.
Initial infection with HCV is typically asymptomatic or mildly symptomatic. The most common symptoms, 
if present, are loss of appetite, abdominal discomfort, nausea and vomiting, and jaundice. Infection is 
rarely detected in the acute phase. Between 15% and 45% of those infected clear the virus spontaneously, 
while the remaining 55% to 85% of those infected develop chronic HCV infection (2). Chronic infection 
can cause liver inflammation, fibrosis, cirrhosis, liver cancer (hepatocellular carcinoma (HCC)), liver failure 
and death. Chronic liver disease develops over many years and signs and symptoms may not be evident 
for 20 to 30 years until serious liver damage has occurred. For this reason, HCV infection is sometimes 
called the ‘silent killer’. An estimated 4% of those with cirrhosis progress to decompensated liver disease 
annually and 1.6% develop HCC annually (3). Progression to chronic liver disease is associated with 
excessive alcohol intake, co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV), 
being male, and older age.
Advancements in new treatments for HCV infection which offer a cure in most cases, and are more 
acceptable to patients, have led to a significant shift in strategy direction for HCV care and policy, with the 
paradigm now focused towards elimination.
1.2. Epidemiology and clinical impact of HCV infection in Ireland
HCV infection, has been a notifiable disease in Ireland since 2004. Between 2004 and 2016, 14,107 
cases were notified. In recent years there has been a decrease in cases, notified (Figure 1). However, the 
number of new cases now appears to be stabilising rather than further declining.
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Figure 1: Number of notifications of HCV 2004-2016, by sex and median age. (Source: HSE Health Protection 
Surveillance Centre)
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Where risk factor data are available, IDU is the most common risk factor reported (80%), followed by 
possible sexual exposure (5%), receipt of blood or blood products (4%), vertical transmission (2%) and 
tattooing or body piercing (1%). In 7% no risk factor was identified.
Notification data can only include diagnosed cases. Information on the prevalence of a disease is a better 
reflection of the burden of disease as it includes undiagnosed cases (4). A 2016 study found that the adult 
seroprevalence of HCV was 0.98% (95% confidence interval (CI) 0.73%-1.3%) and the adult prevalence of 
chronic HCV infection was 0.57% (95% CI 0.40%-0.81%) (5). Based on this and other available data it is 
likely that there are between 20,100 and 42,000 people with current infection in Ireland, and that 60% of 
those have not yet been diagnosed (4, 6).
The number of hospital admissions due to end stage liver disease (ESLD) and HCC in those with HCV 
infection has been increasing in Ireland. This increase is likely related to the fact that the peak incidence 
in the largest risk group, people who inject drugs (PWID), in Ireland was in the late 1990s, and those 
infected during that period are now developing ESLD or HCC (7). Between 2005 and 2016, 116 liver 
transplants were performed in Ireland in people with HCV infection, accounting for 18% of all liver 
transplants (source: HIPE via Health Atlas Ireland1 (8)).
HCV related morbidity and mortality, and also healthcare resource use, may not yet have peaked. 
Modelling studies in the UK predicted that, at current treatment levels, the incidence of ESLD would 
continue to increase, peaking in 2030 (9).
1.3. National and international policy
National Hepatitis C Strategy
The National Hepatitis C Strategy 2011-2014 was the first published strategy relating to all those infected 
with HCV in Ireland (10). The strategy spans surveillance, prevention, screening and treatment of HCV 
infection. While progress has been made in a number of the strategy’s recommendations, particularly 
those relating to treatment since the establishment of a National Hepatitis C Treatment Programme (HSE 
NHCTP), many are still to be implemented. 
National Hepatitis C Treatment Programme
Direct acting antiviral (DAA) therapies are now the standard of care for HCV infection (11). In HCV 
treatment, sustained virological response (SVR) means that the virus is no longer detectable at a defined 
period after completion of therapy. SVR is regarded as a virological cure and is associated with improved 
morbidity and mortality. Older treatment regimes induced SVR rates of 40-65% (2). DAA treatment 
regimes are of shorter duration, with far fewer side effects, and have SVR rates of over 90% (2). Further 
details on the new treatments are available at http://www.hse.ie/eng/health/az/H/Hepatitis-C/
It is now recommended that DAA regimens be used for the treatment of persons with HCV infection (2, 
12). In order to ensure the most appropriate management of access to these costly new drugs, an Expert 
Advisory Group was established by the Department of Health (DoH) in 2014 and chaired by the Deputy 
Chief Medical Officer. The role of the advisory group was to advise on the feasibility of a multi-annual 
public health treatment plan for patients with HCV infection based on clinical prioritisation criteria. The 
DoH subsequently published a report: A Public Health Plan for the Therapeutic Treatment of Hepatitis C 
in 2015 which recommended the establishment of the NHCTP in the HSE (13).
____________________________
1  Based on a procedural code of ‘Transplantation of liver’ (9031700) AND a diagnostic code of  HCV infection (B182). Extracted 10 July 2017.
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Access to treatment in Ireland has been introduced through the HSE NHCTP on a phased basis based on 
clinical criteria with those having greatest clinical need receiving treatment initially. Criteria for treatment 
are determined by the HSE NHCTP Programme Advisory Group (PAG). Criteria for access to treatment 
are continuously expanding. The HSE NHCTP is aiming to provide treatment across a range of healthcare 
settings to all persons living with HCV in Ireland over the coming years with a view to successfully 
eliminating the HCV in Ireland and making it a rare disease by 2030 (14).
In order to achieve this, all at risk groups must be identified, screened and linked to treatment and care. 
Implementation of this National Clinical Guideline will be key to the identification and screening of people 
with undiagnosed HCV infection.
International policy
The first global health sector strategy on viral hepatitis, covering the period 2016–2021 was published 
by the World Health Organization (WHO) in 2016 (15). The vision of the strategy is “A world where viral 
hepatitis transmission is halted and everyone living with viral hepatitis has access to safe, affordable and 
effective prevention, care and treatment services“. It sets the goal of eliminating viral hepatitis as a major 
public health threat by 2030 by reaching the target of 90% of those infected being diagnosed and 80% of 
those eligible having been treated. The strategy calls for action across the entire continuum of hepatitis 
care from primary prevention of infection, to diagnosis, linkage to care, and treatment.
1.4 Principles of screening
Screening can be defined as “the presumptive identification of unrecognized disease or defects by means 
of tests, examinations, or other procedures that can be applied rapidly”(16).
Screening for HCV infection meets all of the criteria by which a proposed screening programe should be 
evaluated (16).
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2 Development of this National Clinical Guideline
2.1. Rationale for this National Clinical Guideline
With the development of new treatments for HCV, the paradigm has shifted towards elimination. Ireland 
has committed to a WHO target to eliminate as a major public health concern HCV by 2030. Key to 
reaching the goal of elimination will be treatment of those infected. However, it is estimated that 60% of 
those with HCV infection in Ireland are undiagnosed. Without screening cases may go undetected for a 
considerable length of time due to the asymptomatic nature of HCV infection.
While there is screening for HCV infection ongoing in many settings in Ireland, there has not been a 
national guideline to guide healthcare providers or services.
WHO has stated that national testing policies are needed, as are increased investments in HCV screening 
services in order to reach the goal of elimination. With the commitment to offer treatment to those 
infected through the establishment of the HSE NHCTP, there has never been a more important time for 
national screening guidelines to be introduced. 
2.2. Aim and objectives
The aim of the guideline is to reduce the overall health and economic impact of HCV infection and 
contribute to the elimination of HCV as a public health concern in Ireland by 2030.
The objectives of the guideline are:
• to make recommendations on who should be offered screening for HCV infection and how screening 
should be undertaken 
• to enhance and further improve the screening of those at risk for HCV
• to improve the identification of undiagnosed cases of HCV
• to reduce variation in practice relating to HCV screening
• to support the linkage to care of identified cases 
• to increase awareness of HCV screening amongst healthcare workers and the public.
2.3. Guideline scope
Population to whom the guideline applies
Those living in Ireland with unrecognised HCV infection.
Intended users of the guideline
All healthcare professionals, healthcare managers and policy makers. The guideline will also be of value 
to both statutory and voluntary agencies providing services to those groups at increased risk of HCV 
infection. It may also be used by those with HCV or in a risk group for HCV and by members of the public.
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2.4. Conflict of interest statement
The guideline development process followed the conflict of interest policy set out by NCEC. All members 
of the GDG were required to complete a Conflict of Interest Declaration which were managed by the 
Chair. Stated conflicts of interest are outlined in Appendix 4 of the full guideline.
2.5. Sources of funding
No external funding was received for the development of this guideline. The commissioned literature (on 
the risk of HCV sexual transmission amongst heterosexuals) review was funded by the National Patient 
Safety Office (NPSO), Department of Health to support the work of the NCEC.
2.6. Guideline development group (GDG)
The GDG included professionals with the relevant expertise and experience, and target users of the 
guidelines. The disciplines represented were infectious diseases, medical microbiology, virology, 
occupational medicine, obstetrics and midwifery, prison health, general practice, addiction services, and 
public health. Healthcare management, at-risk groups, and patients were also represented. Members of 
the GDG are listed in Table 1.
2.7. Methodology and literature review
The key questions to be addressed by the guideline were identified from the recommendations of the 
National Hepatitis C Strategy and through consultation with the GDG. Key questions are outlined in 
Appendix 5.
Recommendations from high quality national or international guidelines were adopted or adapted where 
feasible. Included guidelines and their quality appraisal scores are summarised in Appendix 6 of the full 
guideline. If a key question was not addressed in existing guidelines, or not adequately addressed, or 
national and international guidelines conflicted in their recommendation, a review of published research 
was conducted. Search strategies were altered to be appropriate to the research question (see Appendix 
7 of the full guideline). One systematic literature review was commissioned and undertaken by the School 
of Nursing and Midwifery, National University of Ireland, Galway (see Appendix 8 of the full guideline).
To formulate recommendations, subgroups of the GDG used a considered judgement process adapted 
from the GRADE Evidence to Decision (EtD) framework (17, 18). Recommendations were formulated 
taking into account the available evidence, the balance of benefits and harms, resource use, acceptability, 
feasibility of implementation, and the known or estimated values and preferences of patients and society 
(links to considered judgement forms are available in Appendix 9 of the full guideline). Recommendations 
were then presented to the full GDG for approval.
2.8. Grading of recommendations
Recommendations were graded in two ways: the level and quality of evidence supporting the 
recommendation (Table 3) and the strength of the recommendation (Table 4), based on recommendations 
from GRADE (19, 20).
Note on the phrasing of recommendations:
In the case of a strong recommendation to screen a certain group, the phrasing used was that those 
within this group ‘should be offered screening’.
In the case of conditional/weak recommendation to screen a certain group, the phrasing used was that 
for those within this group ‘screening should be considered’.
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Table 3: Categorisation of evidence
Level of evidence Type of evidence Rationale
High Consistent evidence from well performed 
randomised, controlled trials, meta-analyses, or 
overwhelming evidence of some other form
Further research is unlikely to change 
our confidence in the estimate of 
benefit and risk
Moderate Evidence from randomised, controlled trials 
with important limitations (inconsistent results, 
methodological flaws, indirect or imprecise), or 
very strong evidence of some other research 
design
Further research (if performed) is likely 
to have an impact on our confidence 
in the estimate of benefit and risk, and 
may change the estimate
Low Evidence from observational studies, consensus 
opinion of experts, case studies, or from 
randomised, controlled trials with serious flaws, 
or standard of care
Any estimate of effect is uncertain
Table 4: Grading of the strength of the recommendation
Strength of recommendation Rationale
Strong The potential positive outcome is highly valued.
The benefits will outweigh the harms or the cost.
Conditional/Weak The potential benefit of the recommendation is uncertain, or the balance 
between benefit and harm, or cost is finely balanced, or dependent on 
other factors. The feasibility of implementation is uncertain or likely to be 
difficult. 
2.9. Stakeholder consultation and external review 
Individuals or organisations identified as stakeholders in the health and social care of those who are 
infected with HCV or at risk of HCV infection, and members of the public were invited to review the 
guideline and provide feedback.
International external review of the guideline was undertaken by two experts in the epidemiology and 
public health management of HCV: Dr Susan Hahné, Senior Epidemiologist and Head of Department 
for Early Warning and Surveillance, National Institute for Public Health and the Environment, the 
Netherlands, and Dr Magdalena Rosińska, Epidemiologist at the National Institute of Public Health - 
National Institute of Hygiene, Poland and current chair of the European Centre for Disease Prevention 
and Control (ECDC) Hepatitis Coordination Committee.
Feedback received was reviewed by the GDG and the guideline was amended where appropriate. Further 
detail on the consultation process, the feedback received and the resulting action of the GDG is available 
in Appendix 10 of the full guideline.
2.10. Procedure to update this National Clinical Guideline
The guideline will be updated three years from publication as per the process recommended by 
NCEC. Responsibility for update of the guideline will rest with the National Hepatitis C Strategy, or a 
future governance structure into which the National Hepatitis C Strategy is incorporated (please see 
Recommendation 27 regarding the need for a national HCV programme). If there is a major change in 
evidence prior to this, a rapid update may be conducted as per NCEC procedures.
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2.11. Implementation 
A plan for implementation of this guideline is available in Appendix 11 of the full guideline. The plan 
builds on the work that is already being undertaken by a range of HSE services, NGOs, health and social 
care professionals, peer workers and volunteers (see Appendix 12 of the full guideline for a summary of 
services). Support for implementation of this guideline has been stated in the HSE Primary Care and HSE 
Health and Wellbeing 2017 operational plans (21, 22).
While the scope of this guideline is limited to screening, it is recognised that, in order to achieve the 
goal of elimination by 2030, action is required across the entire continuum of HCV care (15). The GDG 
recommends that a National Hepatitis C programme with a mandate and resources to co-ordinate actions 
across the entire continuum of care should be established, as recommended by WHO. 
2.12. Economic impact of this National Clinical Guideline
A review of economic literature was undertaken to inform the guideline process and, where appropriate, 
was considered in the formulation of recommendations. A summary of economic evidence is presented in 
Appendix 13 of the full guideline. Of note, much of the economic evidence was based on older treatment 
regimes and therefore not generalisable to the current and rapidly changing HCV treatment context.
A Budget Impact Assessment (BIA) is also presented in Appendix 13 of the full guideline. It has been 
estimated that implementation of the guideline will cost is €1.1 million per year over a five year period.
Funding for implementation of this guideline will be subject to the HSE service planning process for 
activities within the HSE and the respective funding methods of other organisations to which it applies.
2.13. Monitoring, evaluation and audit
Implementation of the guideline will span a range of sectors and services. Monitoring and evaluation 
will be required at individual service level, and national service level. Suggested monitoring and audit 
criteria are presented in Appendix 14 of the full guideline. It is recommended that sectors implement 
a standardised audit plan to allow for audit data from individual services to be collated and fed into a 
national audit process.
Appendix 14 of the full guideline presents metrics which reflect key areas of this guideline which should 
be considered for inclusion as national key performance indicators.
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3 National Clinical Guideline recommendations
3.1. Should the following people be offered screening for HCV?
3.1.1. Pregnant women 
One of the primary aims of screening pregnant women for infections is to intervene if possible and 
prevent vertical (mother-to-child) transmission of the infection and adverse outcomes for the child.
The risk of vertical transmission of HCV is approximately 4-8% and is substantially higher in infants born 
to mothers who are also HIV-infected (10.8–25%) (2). The risk of transmission is correlated with the HCV 
viral load of the mother. There are currently no interventions which have been shown to significantly 
reduce the risk of vertical transmission of HCV and routine obstetric care is recommended (23-28). 
Currently, HCV treatment during pregnancy is not recommended.
A number of studies have reported on the prevalence of HCV in the antenatal population in Ireland. 
A study in 1997-1998 in the Rotunda Hospital determined the prevalence of anti-HCV in an antenatal 
population to be 0.9% (29). In a study comparing targeted screening (i.e. only women with risk factors) 
and universal screening (i.e. all women) over consecutive years (2006 and 2007) in the Coombe Women 
& Infants University Hospital, the prevalence of anti-HCV was found to be 1.4% in the targeted screening 
programme and 0.7% in the universal screening programme (30). Approximately half of women attending 
for antenatal care were eligible for screening as part of the targeted screening programme (30). It was 
estimated that in the universal programme, one case (1/67, 1.5%) would not have been detected through 
a targeted screening programme.
Value judgement
The beneficial effects of universal screening in pregnancy do not outweigh the potential cost at present 
as treatment for HCV infection is not available in pregnancy and there are no interventions to reduce 
transmission to infant. The prevalence of HCV in the general antenatal population in Ireland is likely to 
be low and standardised implementation of targeted risk-based screening is likely to detect most cases 
of maternal HCV infection. If HCV treatment during pregnancy becomes feasible in the future, the value 
judgement may shift in favour of universal HCV screening in pregnancy. 
Recommendation 1
1.1 Standardised targeted risk based HCV screening of antenatal women is recommended (see 
Appendix 1 for a list of risk populations). 
1.2 Universal HCV screening of antenatal women is not recommended.
1.3 Universal antenatal HCV screening may be reconsidered in the future if HCV treatment during 
pregnancy becomes possible. Also, if national policy progresses to a policy of birth cohort or total 
population screening, antenatal screening offers an opportunistic method to reach this particular 
population cohort. 
Quality/level of evidence: moderate; good consistency between existing high quality guidelines
Strength of recommendation: strong
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3.1.2. Children born to mothers with HCV infection
There is a small risk of transmission of HCV between an infected mother and her infant during the perinatal 
period (see section 3.1.1). There is no risk of vertical transmission if a mother is not viraemic (i.e. HCV-RNA 
negative).
Screening of infants born to infected women permits early identification and linkage to care.
Due to the transfer of maternal anti-HCV across the placenta, infants born to infected mothers may be 
anti-HCV positive in the first few months of life, in the absence of vertical transmission of HCV infection. 
Due to this persistence of maternal anti-HCV, serological testing of infants is not recommended before 12 
months of age (23, 27). Testing for HCV-RNA can be undertaken earlier. However, the sensitivity of HCV-
RNA in early life is low and confirmatory testing will be required at a later stage.
Current practice in Ireland, as per the Rainbow Clinic2 guidelines, is to offer HCV-RNA testing at six weeks 
and six months of age (24). If HCV-RNA is negative, absence of infection is confirmed with an anti-HCV 
test at 18 months of age. If HCV-RNA is positive at any stage, the infant is referred to the Rainbow Clinic. 
This testing and referral system has been in place in Ireland for a number of years and is functioning 
efficiently. It is the experience of the Rainbow Clinic that this testing schedule enables early linkage to 
care for a sometimes vulnerable population and enables the family to be supported through subsequent 
follow-up, thus reducing the risk of losing contact with the family and infant.
Value judgement
While the GDG recognises that there is not a direct clinical benefit to detecting infection in infants early, 
the GDG recommends adopting the Rainbow Clinic guidelines on the basis that they have proven to be 
acceptable and feasible, and that the early testing schedule will link the child and family into care and 
support subsequent follow-up.
Recommendation 2
2.1 Infants of HCV-RNA positive women should be tested for HCV-RNA at six weeks and six months of 
age and, if both are negative, anti-HCV at ≥ 18 months of age.
2.2 Infants who are HCV-RNA positive at any time, or who are anti-HCV positive at or after 18 months 
of age, should be referred to the Rainbow Clinic.
2.3 Infants of anti-HCV positive but HCV-RNA negative women, where eradication of infection, either 
spontaneously or by treatment is not assured (i.e. by serial negative HCV-RNA tests), should be 
tested for anti-HCV at ≥18 months of age. 
2.4 Infants of anti-HCV positive but HCV-RNA negative women, where eradication of infection, 
spontaneously or by treatment is assured (i.e. persistent negative HCV-RNA tests and no ongoing risk 
for reinfection), should be managed as infants of uninfected women and do not require follow-up. 
Quality/level of evidence: low to moderate
Strength of recommendation: strong
Recommendation 3
3.1 If a woman is found to have current or resolved HCV infection, any previous children she has given 
birth to should be tested for HCV, unless the woman was known to be HCV-RNA  negative at the 
time of their delivery.
Quality/level of evidence: low to moderate
Strength of recommendation: strong
____________________________
2 The Rainbow clinic is Ireland’s national centre for paediatric infectious diseases. The service is delivered by a multidisciplinary team in Our 
Lady’s Children’s Hospital, Crumlin and Children’s University Hospital, Temple Street.
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3.1.3. Household contacts of a person with HCV infection
Household contacts are people who share living spaces with each other. They can be spouses, partners, 
siblings, children or other family members, or be unrelated. Transmission of HCV to a household 
contact (excluding vertical or sexual transmission) is termed horizontal transmission. When horizontal 
transmission occurs between family members it is sometimes termed intrafamilial transmission.
Some studies have identified a risk of horizontal transmission of HCV (31, 32). Other studies have found 
no increase or only a slight increase in the prevalence of anti-HCV amongst family members or household 
contacts of a HCV positive individual (33-35).
The epidemiology and routes of transmission between household members are difficult to interpret 
with any certainty. A number of studies showing an increased risk were undertaken in high endemicity 
countries where the potential for exposure through other routes outside of the household (e.g. 
healthcare transmission) could have existed. Even those studies in non-endemic countries were not able 
to differentiate between sexual transmission, horizontal transmission, or other possible transmission 
pathways external to the household. 
Value judgement
While household transmission can occur, the risk is difficult to quantify and it is difficult to eliminate the 
contribution of other common exposures amongst household members. The risk of horizontal non-sexual 
transmission to other household contacts is likely to be very low within normal household settings. The 
experience of the GDG members is that household horizontal transmission is rare. Promoting screening of 
household contacts may lead to undue concern amongst those who are HCV positive or their household 
contacts over the risk posed. It may also lead to stigmatisation of HCV positive people.
Given that the risk within a normal household setting is likely to be low, the possible harms to the HCV 
infected person and the resources that would be required for implementation, active screening of all 
household contacts is not considered justified. The GDG recognises that there are circumstances within a 
household which may increase the risk, and screening should be considered in such circumstances.
Recommendation 4
Where a household contact is a child who was born to an infected mother or a sexual contact of a HCV-
infected person please refer to Recommendation 2 and Recommendation 13, respectively. 
4.1 In general, HCV screening of household contacts (with no sexual or vertical exposure to the 
HCV positive household member) is not necessary due to the low risk of horizontal household 
transmission. However, there may be circumstances where household transmission is more likely 
to have occurred. Screening may be considered based on clinical judgement or a risk assessment 
for factors such as:
• HIV co-infection or high HCV viral load in the HCV positive household member
• A history of current injecting drug use in the HCV positive household member
• If there has been a potential exposure to blood of the HCV positive household member e.g. 
sharing razors
• If the HCV positive household member is on dialysis in the home
• If there are environmental risks within the household such as discarded needles.
4.2 Where a household contact requests testing for reassurance, this should not be denied.
Quality/level of evidence: low; inconsistent recommendations from existing guidelines
Strength of recommendation: conditional/weak
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3.1.4. People who use unprescribed or illicit drugs
People who inject drugs (PWID) are a well-recognised risk-group for HCV infection globally. Current PWID 
are at ongoing risk of infection and regular re-testing has been recommended, although recommendations 
on the frequency of re-testing vary (23, 36). The current standard of care for services offering opioid 
substitution in Ireland is to offer anti-HCV testing on presentation (37). If a patient initially tests negative, a 
repeat test is to be offered every six to 12 months if the patient continues with risk-taking behaviour.
There is limited and inconsistent evidence on the risk of HCV amongst non-injecting drug users. A 
systematic review published in 2007 determined the prevalence of HCV in those engaging in non-injecting 
drug use (NIDU) to range from 2.3-35.5% (median = 14%) (38). However, the authors concluded that it 
could not be adequately determined whether NIDU was associated with HCV infection due to the low 
quality of evidence available. A number of observational studies have reported an association between 
HCV infection and intranasal cocaine use even after adjusting for other possible risk factors, including a 
history of IDU (39-41). Other observational studies have found an association between sharing equipment 
for snorting or sniffing drugs and HCV infection (42-44). However, the quality of studies is limited by a 
lack of clarity on the definition of NIDU used, and reliance on self-reported behaviours.
Value judgement
PWID are a recognised risk group for HCV infection. NIDU which results in exposure to blood of another 
person is a biologically plausible transmission route. Sharing of implements to snort drugs is likely a risk 
due to the highly vascular structure of the nasal passages which can be easily damaged by the insertion 
of implements. Certain drugs which are smoked can cause burning or bleeding of the lips which may pose 
a risk of transmission.
Recommendation 5
5.1 All those who have ever injected unprescribed or illicit drugs should be offered screening for HCV. 
This includes those who only injected once, and those who injected any type of drug which was 
not prescribed, including performance enhancing drugs like steroids, and novel psychoactive 
substances.
5.2 Re-testing of those who test HCV negative should be offered on an annual basis, or six monthly if 
deemed clinically appropriate*, for those who remain at ongoing risk of infection. 
5.3 Testing should be available during this interval if a risk exposure is known to have occurred.
5.4 Re-testing for those who have been previously infected, but have cleared infection spontaneously 
or through treatment, should be done by HCV-RNA testing, as anti-HCV antibody remains positive 
after the first infection.
*More frequent testing may be considered in circumstances such as: if a risk exposure is known to have 
occurred; an unexplained rise in alanine aminotransferase (ALT); a diagnosis of another bloodborne virus (BBV).
Quality/level of evidence: high; good consistency between existing high quality guidelines
Strength of recommendation: strong
Recommendation 6
6.1 Screening should be offered to all those who have used unprescribed or illicit drugs by a route 
other than injecting (i.e. non-injecting drug use (NIDU)), if there is a possibility of transmission of 
HCV by the route of administration. This includes those who currently use intranasal drugs (i.e. 
snort or sniff), or have done so in the past, or share other equipment or drugs where there is a risk 
of contamination with the blood of others (e.g. smoking crack pipes).
Quality/level of evidence: low
Strength of recommendation: strong
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3.1.5. Prisoners
Prisoners are a recognised risk group for HCV infection globally (2). Prisoners are considered to be a risk 
group mainly due to the association between IDU, criminality and imprisonment. However, there is a risk 
of transmission within the prison setting due to factors such as IDU and equipment sharing, tattooing, or 
other environmental exposure to contaminated blood while in prison.
Studies have demonstrated a high prevalence of IDU amongst prisoners in Ireland and a high prevalence 
of HCV (45-47). In a 2011 study, an anti-HCV prevalence of 13% (95% CI 10.9-15.2%) was found amongst 
prisoners (45). Amongst those who were also PWID, the anti-HCV prevalence was 41.5%.
The Irish Prison Service Health Care Standards recommend that all those entering prison be offered HCV 
testing where clinically appropriate and that prisoners who are infected with HCV be given appropriate 
advice and treatment (48). However, uptake of HCV screening by prisoners is reported to be low. There 
are a number of possible reasons for this. Upon committal a prisoner may have many other worries and 
concerns and HCV screening may not be considered a priority for them. Concerns about confidentiality 
may also be a barrier to accepting an offer of screening in prison.
Value judgement
In general, prisoners are from marginalised groups who are otherwise poorly reached by healthcare 
services. Their time in prison may offer a unique opportunity for the diagnosis, assessment and treatment 
of HCV infection. There are new initiatives underway within some Irish prisons to offer treatment to 
prisoners within the prison setting, in addition to some of the current in-reach programmes provided by 
hospital based services and supported by the HSE NHCTP.
Screening should be undertaken early during committal to enable an opportunity to link into care, and to 
minimise the risk of transmission to others within the prison setting. Novel approaches will be required to 
improve uptake. 
Recommendation 7
7.1 Screening for HCV should be offered to all prisoners on entry to prison. Screening should be offered 
at a time at which it is most likely to be accepted by the prisoner, while also ensuring the early 
identification of infections in order to minimise the risk of transmission to others.
7.2 Those found to have HCV infection should be linked into specialist care and treatment should be 
facilitated while in prison.
7.3 Prisoners who initially test HCV negative should be offered repeat testing on an annual basis, or six 
monthly if deemed clinically appropriate*, while in prison. Screening should also be offered at any 
time if a risk exposure (e.g. tattooing, needle-sharing) is known to have occurred. 
7.4 Prisoners should be able to access testing on request at any stage of their sentence. 
*More frequent testing may be considered in circumstances such as: if a risk exposure is known to have 
occurred; an unexplained rise in ALT; a diagnosis of another BBV.
Quality/level of evidence: moderate; good consistency between existing high quality guidelines
Strength of recommendation: strong
Recommendation 8
8.1. One-off testing of ex-prisoners should be considered, although implementation may be difficult.
Quality/level of evidence: moderate; good consistency between existing high quality guidelines
Strength of recommendation: conditional/weak
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Good practice points
• Education on the risk of HCV should be provided upon entry into prison.
• At the time of committal, the interviewing nurse or doctor is best placed to identify the optimal time 
to carry out HCV screening on an individual prisoner.
• Continuity of care and/or treatment on discharge from prison should be ensured. This should 
be considered as part of discharge planning. Continuity of care on entry to prison should also be 
considered.
• Communication about test results or treatment should occur between the prison health service and 
the prisoner’s GP, or other services attended by the prisoner, such as addiction services or psychiatric 
services.
• Confidentiality at the time of screening offer, during testing, and when communicating results 
of testing should be ensured as far as possible while still ensuring a safe environment for prison 
healthcare staff.
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3.1.6. People who are homeless
A number of studies in Ireland have shown an association between some homeless populations such as 
rough sleepers, IDU and HCV infection (49-51).
The results of these studies are consistent with the experiences of members of the GDG working with 
people who are homeless. However, studies have been mainly concentrated in Dublin, and the association 
may not be reflected in other regions. Also, in recent years there may be an increasing number of people 
becoming homeless due to altered financial circumstances, and these people may not have the same risk 
profile.
While IDU is the main reason that some people who are homeless are at risk of HCV infection, other risk 
factors may be present, such as being from a country where HCV is common. Also, those who do not use 
drugs but share sleeping space with drug users may have been exposed to environmental risks, such as 
discarded needles. 
Value judgement
The homeless are a marginalised group with often greater healthcare needs than other population 
groups. Homeless people who are PWID are a particularly vulnerable population who are sometimes 
poorly reached by health and addiction services. Extra support will be required to pro-actively identify 
and access this population, and to facilitate uptake of screening. In addition, support will be required to 
enable linkage to care and treatment.
Recommendation 9
9.1 Homeless people who have a history of engaging in risk behaviours associated with HCV 
transmission, or who have had a potential HCV risk exposure, should be offered screening. 
9.2 Those who initially test HCV negative should be offered repeat testing on an annual basis, or six 
monthly if deemed clinically appropriate*, if there is an ongoing risk of transmission.
*More frequent testing may be considered in circumstances such as: if a risk exposure is known to have 
occurred; an unexplained rise in ALT; a diagnosis of another BBV.
Quality/level of evidence: low
Strength of recommendation: strong
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3.1.7. Migrants
WHO recommends that migrant3 populations from high/intermediate endemic countries be offered 
screening (52). However, at present in Ireland, apart from screening being offered to asylum seekers and 
some screening of migrants attending antenatal services, screening for migrants is not routine.
There is limited data available on the prevalence of HCV among migrants living in Ireland. The Reception 
Centre in Balseskin reported that, amongst those accepting voluntary screening between 2004 and 
2012, the prevalence of HCV was 0.95%, with a prevalence of 3.3% amongst certain nationalities (53). An 
audit of screening services provided to asylum seekers presenting to reception centre clinics in what was 
previously the Eastern Region Health Authority (ERHA) determined that between 1999 and 2003 the anti-
HCV prevalence amongst those screened was 1.5% (54).
Migrants from high prevalence countries can have a prevalence of HCV comparable to their country of 
origin (55). There is some evidence that even when the prevalence is lower than the prevalence in the 
country of origin, it is still higher than that of the general population of the country of residence (55).
It has been estimated that adult migrants contribute 20% (lowest to highest estimate: 7- 47%) of the total 
burden of chronic HCV cases in Ireland (55). Based on the census data, and assuming a prevalence equal 
to that in their country of origin, it is estimated that there could be 8,000 migrants in Ireland with HCV 
infection. 
Value judgement
One-off screening of migrants from intermediate to high prevalence countries would potentially detect 
half of chronic infections amongst migrants. While the recommendation will result in a large number 
of people being eligible for screening, given the increased risk of chronic infection in migrants, it is 
considered appropriate to offer screening to those from a country with a prevalence greater than 2%.
This recommendation and its implementation must not lead to any stigmatisation. There may be 
economic, language or cultural barriers to migrants accessing healthcare and testing, in particular 
migrants who are undocumented, and these should be addressed. 
Recommendation 10
10.1 Migrants from a country with an intermediate to high prevalence of HCV (anti-HCV ≥ 2%*) should 
be offered one-off HCV screening.
*Please refer to Appendix 2 for a list of countries with an anti-HCV prevalence ≥ 2%.
Quality/level of evidence: low to moderate
Strength of recommendation: strong
____________________________
3 The term migrant in this guideline refers to anyone born outside of Ireland but currently living in Ireland. See glossary for definition.
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3.1.8. People who received medical or dental treatment abroad
There is limited evidence on the risk of HCV transmission from medical or dental treatment abroad. 
However, WHO recognises that there is a risk of parenteral transmission of HCV in healthcare settings 
where there is a higher background prevalence of HCV and where infection control practices are 
inadequate, and where blood transfusions and other tissue donations are not screened for viral hepatitis 
(52). WHO thus recommends that persons who have received medical or dental interventions in health-
care settings where infection control practices are substandard should be offered testing for HCV (2).
The number of Irish residents who travel abroad for medical and dental treatment, and the countries 
they travel to, is not known. In addition, the number of people resident in Ireland who may have received 
medical or dental treatment while travelling or living abroad is not known.
It is recognised that implementation of this recommendation will be difficult and will be likely to be on an 
opportunistic basis.
Recommendation 11 
11.1 Screening for HCV should be considered in people who have received medical or dental treatment 
in countries where HCV is common (anti-HCV prevalence ≥ 2%*) and where infection control may 
be poor.
*Please see Appendix 2 for a list of countries with anti-HCV prevalence of ≥ 2%.
Quality/level of evidence: low
Strength of recommendation: conditional/weak
21| A National Clinical Guideline – Summary | Hepatitis C Screening
3.1.9. People with tattoos or body piercings
A number of studies have identified an association between tattooing and HCV infection (56). When 
stratified by the place where the tattoo was done the association persisted for tattoos carried out in non-
professional parlours or by ‘friends’ but was lower and not significant for tattoos done in professional 
parlours.
A number of studies have found that the association between tattooing and HCV infection differs by 
the date of tattooing. In a study in Australia, the highest association was found amongst those tattooed 
between 1980 and 1990. In a study amongst blood donors in Canada in 2006, having received a tattoo 
more than 10 years ago was significantly associated with HCV infection, while receiving a tattoo within 
the last 10 years was not (57).
No studies, outside of the prison context, were identified which determined the risk of HCV from tattoos 
in Ireland.
A number of observational studies found an association between HCV infection and ear piercing, body 
piercing, or an unspecified piercing, on univariable analysis (58-62). However, when multivariable analysis 
was undertaken the associations generally did not persist (57, 58, 60, 62). Other observational studies did 
not find an association with HCV infection and piercing (60, 63-67).
Value judgement
The evidence demonstrates a link between tattooing and HCV infection. The factors associated with 
increased risk of transmission are not clear but it is likely that those most at risk of having acquired HCV 
through tattooing are those who received tattoos a long time ago, in non-professional settings, in prison, 
in high prevalence countries, or in other circumstances where infection control was poor. While many 
commercial premises are likely to employ appropriate infection prevention and control practices, there is 
no regulation of the industry in Ireland to assure standards. For this reason, offering HCV screening to all 
recipients of tattoos should be considered.
The evidence on the risk of HCV transmission with body piercing is inconsistent and limited in quantity 
and quality, and thus does not support a recommendation for offering screening to those with body 
piercings.
Recommendation 12
12.1 Screening for HCV should be considered for all those with a tattoo. Those most at risk of having 
acquired HCV through tattooing are those who received tattoos a number of decades ago, in non-
professional settings, in prison, in high prevalence countries, or in other circumstances where 
infection control was poor.
12.2 There is insufficient evidence to support screening of recipients of body piercings (including ear 
piercings).
Quality/level of evidence: low; good consistency between existing high quality guidelines on screening of 
those with tattoos
Strength of recommendation: conditional/weak
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3.1.10. Heterosexual partners of a person with HCV or a person at risk of HCV infection
The risk of sexual transmission of HCV is strongly linked to HIV co-infection and there is low or no risk of 
sexual transmission of HCV among HIV-negative heterosexual couples (2, 52, 68-71).
Amongst heterosexuals, outside of the context of monogamous relationships, there is limited evidence 
on what, if any, sexual behaviours present an increased risk of sexual transmission of HCV. The risk 
associated with multiple sexual partners or sexually transmitted infections is not clear (72). WHO states 
that overall the risk of sexual transmission of HCV is low amongst sex workers. However, there may be 
a small increased risk of transmission among persons with multiple sex partners which may place sex 
workers at increased risk. Also, sex workers may be more likely to belong to other high risk populations, 
such as PWID (52). In a systematic review to determine what factors were associated with an increased 
risk of sexual transmission of HCV infection in a heterosexual population, the included studies examined 
seven risk factors (multiple sex partners, receiving or providing sex commercially, having a PWID partner, 
and unprotected vaginal, oral or anal sex) (73). One included study in an antenatal population in Scotland, 
found an increased risk of HCV amongst those who reported not injecting drugs but had a sexual partner 
who did (74). None of the other factors examined in the systematic review were found to be statistically 
significant risk factors. However, the authors concluded that there was uncertainty about these results 
due to limited quantity of evidence and the very low quality of evidence.
Value judgement
Testing of heterosexual sexual partners of people who are HCV positive is not routine practice in most 
settings in Ireland at present. The risk of sexual transmission amongst heterosexual partners is low. 
However, there are circumstances that increase the risk of sexual transmission, including if either partner is 
HIV positive.
There is no clear evidence to suggest that any particular sexual practices or behaviours increase the risk 
of sexual transmission amongst heterosexuals. There is very limited evidence that sexual partners of PWID 
and commercial sex workers may be at increased risk of HCV infection. This may be due to other non-sexual 
transmission routes of exposure.
Recommendation 13
13.1. In general, HCV screening of sexual partners of known HCV cases is not recommended in 
heterosexual couples who are both HIV negative.
13.2. Sexual partners of known HCV cases should be considered for screening in the following situations: 
a) If the HCV infected case is a PWID.*
b) If the case or contact is also HIV positive.
13.3. Sexual contacts of PWID, but whose HCV status is unknown or where there is evidence of resolved 
infection, should be considered for screening.
13.4. If testing of a sexual partner of a HCV-infected case is requested for reassurance, then this should 
not be denied.
*Partners of HCV-infected PWID may be at increased risk as they may themselves have a history of IDU, 
or due to environmental exposure to discarded needles, or they may have been involved in commercial 
sex work.
Quality/level of evidence: low 
Strength of recommendation: conditional/weak
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3.1.11. Men who have sex with men
To date, the risk of sexual transmission of HCV amongst men who have sex with men (MSM) who are 
HIV negative has been considered to be low (2). A number of systematic reviews and meta-analyses 
have shown an increased prevalence or incidence of HCV amongst HIV positive MSM compared to HIV 
negative MSM, in particular HIV positive MSM who are PWID (75-77).
Mucosal damage is proposed as the facilitator of sexual transmission of HCV amongst MSM. Studies have 
shown sexual transmission of HCV amongst MSM to be associated with unprotected anal intercourse 
(UAI); the number of sexual partners; recent ulcerative sexually transmitted infections (STIs), in particular 
syphilis and lymphogranuloma venereum (LGV); group sex; fisting; rectal trauma with bleeding; use of 
sex toys/and or anal enema; and recreational drug use before or during sex (e.g. chemsex3) (70, 77-80). 
Some drugs used for chemsex are injected, which may pose a transmission risk. Another mechanism by 
which chemsex may increase the risk of HCV infection is due to less safe sex and mucosal trauma due to 
disinhibition.
HCV amongst MSM in Ireland
A cluster of acute HCV amongst MSM in Ireland was reported in 2016 (81). Twenty percent of cases 
involved in this cluster were HIV negative. An increase in notifications of HCV in men identified as MSM 
has also been observed in the national HCV surveillance system. During 2016, there were 28 cases, 
compared to eight, three and 13 in the previous three years (source: Computerised Infectious Disease 
Reporting system before (CIDR), HSE HPSC). In both the cluster and the notification system, a high 
proportion of cases have had multiple STI events suggesting that transmission may be occurring in a 
particularly high risk group.
Value judgement
HCV amongst MSM in Ireland is an emerging issue. The risk appears to be particularly high in those who 
are co-infected with HIV and in those who engage in high risk sexual behaviour. However, cases have 
occurred in HIV negative MSM.
There is evidence of high risk sexual and drug taking behaviour amongst some MSM in Ireland as 
reported by the Men who have Sex with Men Internet Survey 2015 and evident in the increasing rates of 
STIs amongst MSM (82, 83). These behaviours may lead to increased HCV transmission amongst MSM. 
Early detection of acute infection in MSM through screening may reduce transmission within MSM sexual 
networks and limit the propagation of the HCV epidemic amongst MSM in Ireland.
Recommendation 14
14.1 HIV positive MSM should be screened at least annually for HCV. More frequent testing may 
be required if clinically indicated, e.g. an unexplained rise in ALT, a diagnosis of a new sexually 
transmitted infection (STI), or if a risk exposure has occurred such as contact with a known case of 
HCV, or other risk behaviours including chemsex. 
14.2 HIV negative MSM should be offered testing annually for HCV as part of an overall STI screen. 
More frequent testing may be required if clinically indicated, e.g. an unexplained rise in ALT, a 
diagnosis of a new STI, or if a risk exposure has occurred such as contact with a known case of 
HCV, or other risk behaviours including chemsex.
Quality/level of evidence: moderate for HIV positive MSM; low for HIV negative MSM 
Strength of recommendation: strong
____________________________
3 The use of recreational drugs for or during sex.
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3.1.12. People attending for a sexual health screen
The risk of sexual transmission of HCV amongst heterosexuals and MSM are presented in sections 3.1.10 
and 3.1.11 respectively.
International recommendations limit the screening of asymptomatic attendees of sexual health services 
to those who fall into other risk groups (23, 84-87).
The risk of sexual transmission of HCV is generally low amongst heterosexuals and there is limited 
evidence on particular high risk behaviours which increase the risk.
Value judgement
A sexual health screen is an opportunity to screen those with other identified risk factors for HCV.
Recommendation 15
See Recommendation 14 for MSM attending for sexual health screening.
15.1. HCV testing should be considered part of routine sexual health screening in the following 
circumstances:
• People who are HIV positive
• Commercial sex workers
• PWID
• If indicated by the clinical history e.g. unexplained jaundice
• When other risk factors for HCV as outlined in this guideline are present*
*See Appendix 1 for a list of risk populations.
Quality/level of evidence: low 
Strength of recommendation: conditional/weak
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3.1.13. People on renal dialysis or who have had a kidney transplant
The dialysis setting is recognised as a high risk environment for the transmission of HCV and other BBVs, in 
the absence of strict infection prevention and control practices, including appropriate screening. In 2014, 
the National Standing Advisory Committee on the Prevention of Transmission of Blood-Borne Diseases 
in the Health-Care Setting updated its guidance on screening requirements in the dialysis setting: Blood-
Borne Viruses in the Haemodialysis, CAPD and Renal Transplantation Setting July 2014 (88). The guidance 
within that document on screening of those commencing or on dialysis is still considered best practice, 
and the GDG recommends that this guidance and any ensuing updates made by the Committee are 
followed.
The national guidance recommended that one-off testing of kidney transplant patients three months 
post-transplant be considered. It also recommended that one-off testing be considered for patients 
transplanted before the introduction of this post-transplant screening, unless known to be HCV infected. 
It is not known to what extent these recommendations on post-transplant screening have been 
implemented. The reasoning behind these recommendations is that it is possible for transmission to 
occur during dialysis just prior to kidney transplant. The GDG considers that screening of this group of 
patients is important to detect any transmission which may have occurred in the final months of dialysis 
prior to transplantation, or in those who were on dialysis in the past and successfully transplanted prior 
to the introduction of screening and current infection prevention and control standards. 
Recommendation 16 
16.1 Patients commencing, or on maintenance, haemodialysis or peritoneal dialysis should be screened 
according to the current recommendations of the National Standing Advisory Committee on the 
Prevention of Transmission of Blood-Borne Diseases in the Health-Care Setting and any ensuing 
updates from this committee.
16.2 All patients having a kidney transplant should be tested for HCV by a combined antigen-antibody 
test, or anti-HCV test AND HCV-RNA at three months post-transplant.
16.3 Patients transplanted before the introduction of the above, unless already known to be HCV 
positive, should be tested on a one-off basis by a combined antigen-antibody test, or anti-HCV 
test AND HCV-RNA to out rule the possible acquisition of HCV infection through past treatment 
for renal failure.
Quality/level of evidence: moderate; good consistency between existing high quality guidelines
Strength of recommendation: strong
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3.1.14. Recipients of substances of human origin
In many countries there have been episodes of HCV transmission related to the receipt of blood or 
blood products, either before HCV was recognised as a disease, or before quality assured blood safety 
programmes were put in place.
In Ireland, 1,694 persons are known to have been infected with HCV through blood or blood components 
(89). Of these, 1,051 were infected through anti-D immunoglobulin, 418 through blood transfusions, and 
225 through clotting factors. Routine testing for HCV was introduced into the blood screening process in 
Ireland in October 1991.
The Irish Blood Transfusion Service (formerly the Blood Transfusion Service Board) has undertaken 
extensive efforts to trace recipients of potentially infectious products previously issued in Ireland (90). 
While the majority of those who received infected or potentially infected blood or blood products in 
Ireland have already been traced and offered screening, a small number of people may not yet have 
been traced or may have previously declined screening. It is not recommended that a further active 
screening programme be established for any remaining unscreened recipients, but that those who 
have not previously come forward be encouraged to present for screening or be offered screening 
opportunistically.
Many high income countries had historical HCV transmission episodes due to infected blood components 
and blood products. There may be historical recipients of unscreened blood or blood products in other 
countries who have not been screened and who are now living in Ireland. Also, in some countries a 
quality assured donor screening programme is still not in place (91). 
Recommendation 17
17.1 Recipients of blood or blood components in Ireland prior to October 1991 who have not yet been 
tested should be offered screening.
17.2 All recipients of anti-D immunoglobulin in Ireland between 1st May 1977 and the end of July 
1979, and 1st March 1991 to 18th February 1994 who have not yet been tested should be offered 
screening. 
17.3 Recipients of plasma-derived clotting factor concentrates in Ireland prior to 1992 who have not 
yet been tested should be offered screening.
17.4 Recipients of blood components and blood products overseas in any country where a quality 
assured blood donor screening programme may not have been in place should be offered 
screening.
Quality/level of evidence: moderate
Strength of recommendation: strong
Recommendation 18
18.1 Screening for HCV should be considered in recipients of solid organ transplants in Ireland who 
have not yet been tested (see Recommendation 16 for recipients of kidney transplants).
Quality/level of evidence: low
Strength of recommendation: conditional/weak
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3.1.15.  Donors of substances of human origin
European Union legislation and national legislation requires that, at a minimum, donors of blood, tissues 
and cells5, and organs must be tested for anti-HCV (92-100).
In addition to the legislative requirement, HCV-RNA testing of blood donations by nucleic acid testing 
(NAT) is considered to be best practice and is current practice in Ireland (101). Regarding the testing of 
donors of tissues, cells, and organs, due to the increased sensitivity of NAT assays. NAT is also encouraged 
as good clinical practice to rule out window period infections, and replaces the need for any quarantine 
or follow-up serological screening (102-104). If NAT is either not done, or the results are not available 
prior to organ donation, testing by a combined HCV-Ag and anti-HCV assay test is recommended rather 
than anti-HCV alone (104).
A national advisory committee for safety and quality of blood, organs and tissues is required to advise on, 
and provide a governance framework for best practice in this area beyond legislative requirements. 
Recommendation 19
19.1 Screening of donors of blood, organ, tissue and cells, including reproductive cells*, should at a 
minimum comply with legislative requirements**.
The following screening is also recommended:
19.2 NAT for HCV-RNA of donors of blood should be performed and the results available prior to the 
use of the donation. The test must be designed and approved for screening of blood donations.
19.3 NAT for HCV-RNA of donors of tissues and cells, including reproductive cells*, and living solid 
organ donors, should be performed in addition to current legislative requirements**. 
19.4 For deceased donors of solid organs:
19.4.1. Anti-HCV and HCV-antigen testing should be done and the results available prior to 
donation***.
19.4.2. NAT should be considered where feasible. NAT results may not be available prior to 
transplantation but NAT should still be performed to ensure the rapid identification of the 
recipients of potentially infectious organs ***.
19.5 Any external laboratories used for microbiological screening of donors should be accredited and 
comply with the standards of the appropriate regulatory authority. Laboratories in Ireland should 
be accredited by the Irish National Accreditation Board (INAB) to undertake testing in compliance 
with the International Standard ISO 15189.
19.6 A national advisory committee on the safety of blood, organs and tissues should be established to 
advise on best practice in relation to donor selection, and testing of potential donors.
*In the case of partner donation of reproductive cells for direct use and when no storage or processing 
of samples will be undertaken, microbiological screening is not required.
**Please refer to the relevant competent authority for legislative requirements6.
***It is acknowledged that in some circumstances the balance of risk and benefit may favour the use of 
potentially infectious donations. Such a risk assessment should be conducted by the transplant centre 
in discussion with an appropriate microbiologist/ virologist.
Quality/level of evidence: moderate
Strength of recommendation: strong
____________________________
5 Legislative requirements for screening of reproductive cells differ from other tissues and cells as less stringent biological testing is 
considered to be justified if the donation is between partners with an intimate physical relationship.
6 The Health Products Regulatory Authority (HPRA) for human blood and blood components and for tissues and cells. The HPRA and the 
HSE for organs intended for transplantation. Within the HSE, Organ Donation Transplant Ireland (ODTI) is responsible for implementation 
of their relevant aspects of legislation.
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3.1.16. General population or birth cohort
WHO states that the best approach to screening will depend on a country’s unique HCV epidemiology. 
It recommends that whenever there is an easily identified demographic group that has a high HCV 
prevalence, such as all individuals born in a certain time period i.e. a birth cohort, routine testing for HCV 
within that cohort will likely be cost-effective and should be considered (52).
A review of epidemiological information was undertaken to determine if a specific birth cohort for which 
HCV screening could be recommended exists in Ireland. Triangulation of data from a number of sources 
indicates that the prevalence of HCV infection in Ireland is highest in those born between 1965 and 1985. 
Data from the national HCV surveillance system shows that, of notifications of HCV reported in Ireland 
between 2004 and 2016, 72.5% fall into the birth cohort 1965-1985 (source: CIDR, HSE HPSC). A HCV 
seroprevalence study conducted in Ireland in 2016 showed that the prevalence of chronic infection was 
significantly higher among persons aged 30-49 years (5). Adult males born between 1965 and 1984 from 
the east of the country had the highest rate of chronic HCV infection.
A study of the incidence of HCV amongst PWID, based on the incidence of IDU, estimated that the annual 
number of new HCV infections among PWID increased steeply from the late 1970s and peaked in 1998 
(7). This finding is consistent with the age-profile identified in the notification data and the seroprevalence 
study.
Value judgement
One-off birth cohort screening offers the advantage of avoiding the need to identify specific risks as the 
basis for screening. Healthcare workers may not be skilled at identifying risk factors, and individuals may 
not recall or wish to disclose a risk factor.
Triangulation of data from a number of sources identified the birth cohort born between 1965 and 
1985 as being most affected by HCV infection in Ireland. Thirty one per cent (n=1,426,156) of the 
Irish population were born between these years. The implementation of any birth cohort screening 
recommendation would require substantial resources and the impact is uncertain as it will be influenced 
by factors such as the uptake of screening and linkage to care.
The GDG considers that there is insufficient cost-effectiveness evidence to support a recommendation 
on birth cohort screening at present. A health technology assessment (HTA) and comprehensive budget 
impact assessment should be undertaken prior to further consideration of birth cohort screening. A 
request to conduct this HTA was submitted to the Health Information and Quality Authority (HIQA) and 
was included in the prioritisation process in March 2017. It scored highly on the required criteria and will 
now be considered for inclusion on the HIQA work programme.
Recommendation 20
20.1 Birth cohort screening cannot be recommended at present due to the likely substantial cost 
implications and uncertain benefit. Such a programme would require a full health technology 
assessment (HTA) and approval of funding prior to being considered.
20.2 Birth cohort screening should be considered if a HTA shows it to be cost effective and affordable 
in the Irish context.
Quality/level of evidence: moderate
Strength of recommendation: conditional/weak
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3.1.17. Healthcare workers
For recommendations on the management of healthcare workers (HCWs) following an exposure to 
potentially infected material, HSPC Guidelines on the Emergency Management of Injuries should be 
consulted (105).
Provider to patient transmission of HCV has been documented, including transmission events in the UK, 
Spain and Germany during cardiovascular, gynaecological or obstetric, and orthopaedic surgery (106-
109). However, the transmission rate from infected HCWs to patients, as determined from published 
patient notification exercises, is low (110). No cases of provider to patient transmission of HCV have been 
reported in Ireland (111, 112).
In 2005 the Department of Health Standing Advisory Committee on the Prevention of Transmission of 
Blood-Borne Diseases in the Health-Care Setting recommended HCV screening of all HCWs who perform 
exposure prone procedures (EPPs) (113). Since 2008 it is policy that all new HSE staff who perform EPPs 
are screened (114, 115).
Value judgement
Although rare, provider to patient transmission of HCV can occur. In the context of healthcare provision 
any risk of provider to patient transmission of HCV needs to be minimised.
While there is negligible risk of provider to patient transmission of HCV in HCWs who do not perform 
EPPs, the offer of HCV screening to all new HCWs confers a personal benefit to HCWs by identifying 
undiagnosed cases and allowing linkage to care and treatment.
Screening of healthcare students early in the course of their training is recommended to identify 
undiagnosed cases and link them to care and treatment and avoid restrictions to their activities during 
training. Successful treatment will avoid implications for their future career choices.
Recommendation 21
21.1. All new healthcare workers should be offered HCV screening on a voluntary basis.
21.2. Mandatory HCV screening of all new HCWs who will perform EPPs is recommended.
21.3. Existing HCWs who perform EPPs and have not yet been screened should be offered HCV screening.
21.4. Mandatory screening of all new healthcare students* is recommended.
21.5. Interval HCV testing of HCWs who perform EPPs is not recommended. However, HCWs should be 
informed of their professional responsibility to seek appropriate assessment if any possible risk 
exposure has occurred.
*This includes students who may be undertaking EPPs as students or in their future careers, such as 
dental, medical, nursing, midwifery, or paramedical students.
Quality/level of evidence: moderate
Strength of recommendation: strong
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3.2. How should screening for HCV be performed?
3.2.1. What test should be used for HCV screening?
WHO recommends that the initial test for HCV infection is a HCV serological assay (i.e. anti-HCV or 
antibody/antigen) (52). If positive this should be directly followed by testing for the detection of HCV-RNA 
to confirm current infection. Detection of HCV core (p22) antigen, with an assay which has comparable 
clinical sensitivity to NAT, is an alternative to diagnose current infection.
Chronic infection is confirmed if an HCV-RNA assay is positive six months after the first positive test. 
Patients with low-level viraemia may require HCV-RNA testing on two or more occasions to confirm 
infection (5, 16).
Those who are HIV positive or immunosuppressed
In a person who is immunosuppressed, antibody may not be generated, resulting in a false negative anti-
HCV. Therefore HCV-RNA testing should be considered in some people who are immunosuppressed if 
HCV infection is suspected and anti-HCV remains negative. 
Those previously infected
As anti-HCV generally remains positive for life, testing should be by HCV-RNA in those who were 
previously infected (23, 25). 
Recent infections
Anti-HCV may not be detectable for three or more months after infection. HCV-RNA will be detectable 
after two weeks. If the potential exposure was recent, HCV-RNA or HCV-Ag should be considered.
Frequency of testing for those at ongoing risk
Repeated testing of those at ongoing risk is recommended, although there is no clear consensus on the 
frequency of repeat testing (23, 25, 68, 86, 116-118). 
Recommendation 22
22.1 Individuals being investigated for evidence of HCV infection should be screened with an anti-HCV 
antibody or combined HCV antigen/antibody EIA screening assay*.
22.2 If the initial HCV EIA is reactive (positive), then the sample should be tested for the presence of 
HCV antigen, or HCV-RNA, to test for current infection.
22.3 Current infection should be confirmed on a second sample and HCV-RNA should be performed (if 
not already performed) and HCV genotyping should be carried out.
22.4 Those individuals with evidence of a resolved HCV infection (i.e. anti-HCV positive and antigen/
RNA negative) should have a further sample drawn after six to 12 months for HCV-RNA testing to 
confirm their resolved infection status.
*In certain patient groups, initial testing should routinely incorporate HCV-antigen or HCV-RNA testing. 
Those are: immunocompromised individuals; children (born to HCV-infected mothers) in the first 18 
months of life; individuals previously treated for HCV infection; sources of needle-sticks; and those at 
risk of recent infection in whom an antibody response might not yet have developed (HCV-RNA testing 
should be performed six weeks post-exposure).
See Figure 4.
Quality/level of evidence: moderate; good consistency between existing high quality guidelines
Strength of recommendation: strong
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Test for anti-HCV antibody or 
combined HCV antigen/antibody 
EIA screening assay*
Negative
Negative
Recent infection suspected?
No
Yes
Yes
No
No evidence of HCV infection
Ongoing risk of infection?
Further testing should be 
performed to resolve the 
discordant result profile. The 
further testing should be 
performed at a laboratory 
with sufficient expertise 
and experience to provide a 
resolution
Further testing not 
required at this stage
Re-test at least annually, or every 6 
months if clinically indicated
Ongoing risk of 
infection?
Positive
Positive
Test for HCV antigen or HCV-RNA*
Consistent with current HCV 
infection. Confirm diagnosis on a 
second sample and test for HCV-
RNA if not previously done. 
Test for genotype
Perform a second anti-HCV assay (either a 
second EIA, or an immunoblot) to confirm 
the initial assay result
Negative/discordant 
with first antibody test
Positive/concordant 
with first antibody test
Consistent with resolved HCV 
infection.
Retest for HCV-RNA after 6-12 
months to confirm resolved infection
*In certain patient groups, initial testing should routinely incorporate HCV antigen or HCV-RNA testing. Those are: 
immunocompromised individuals; individuals previously treated for HCV infection; and those at risk of recent 
infection in whom an antibody response might not yet have developed (HCV-RNA testing should be performed 6 
weeks post-exposure).
Figure 4: Testing sequence for HCV infection
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Recommendation 23
23.1 Individuals who initially test HCV negative but who remain at risk of HCV infection should be 
offered repeat testing on an annual basis, or six monthly if deemed clinically appropriate*.
*More frequent testing may be considered in circumstances such as: if a risk exposure is known to have 
occurred; an unexplained rise in ALT; a diagnosis of another BBV.
Quality/level of evidence: low
Strength of recommendation: strong
33| A National Clinical Guideline – Summary | Hepatitis C Screening
3.2.2. What specimen type should be used for HCV screening?
Anti-HCV testing can be performed on a number of different types of specimens including serum, plasma, 
dried blood spots (DBS), and oral fluid. HCV-RNA testing is restricted to serum, plasma or DBS.
Studies examining the performance of DBS in the diagnosis of HCV have found the sensitivity and 
specificity of DBS in detecting anti-HCV to be high (119-125). WHO and other bodies state that DBS 
specimens for anti-HCV testing may be considered in settings where there are no facilities or expertise to 
take venous whole blood specimens, where there are persons with poor venous access or where rapid 
diagnostic tests are not available or their use is not feasible (23, 52, 86).
Studies examining the performance of saliva/oral fluid specimens in the diagnosis of HCV have found 
the sensitivity of oral fluid in detecting anti-HCV to be lower than DBS (125-130). Amongst HIV positive 
individuals, the sensitivity was particularly reduced (126).
In a systematic review of studies that contained quantitative data on the frequency of testing and/or new 
diagnoses after the introduction of DBS testing of high-risk populations, five of the six included studies 
provided evidence that the introduction of DBS testing increased the number of tests, new diagnosis or 
both (131). However, variable effect sizes were found and all included studies that were judged to have 
a high risk of bias. In a qualitative study exploring the acceptability of oral fluid specimen collection, DBS 
from finger-prick, and venepuncture amongst PWID, all three collection methods were found to be highly 
acceptable (132). Oral fluid sampling was reported as the preferred method of testing and finger-prick 
was the least preferred method.
Value judgement
Alternative specimen types such as DBS and oral fluid offer potential advantages over venous blood. 
There is some evidence to support improved acceptability and uptake of testing with DBS or oral fluid, 
although it is still limited. However, the sensitivity of testing on oral fluid samples is low, and therefore it 
is not considered an acceptable specimen.
While the sensitivity of DBS is considered acceptable, there are some limitations There is currently no 
approved laboratory assay for use with DBS specimens. In the absence of an authorised commercial 
assay, considerable resources would need to be invested in validation, standardisation, quality assurance 
and quality control.
Recommendation 24
24.1. Serum and plasma are the preferred specimen types for screening and diagnostic testing for HCV 
infection using quality assured assays.
24.2. Screening and diagnostic testing for HCV infection should not be performed on oral fluid samples 
due to the low sensitivity and low positive predictive value.
24.3. Dried blood spot testing can be considered for screening for HCV in special circumstances, such as 
mass screening initiatives e.g. in prisons. 
Quality/level of evidence: moderate; good consistency between existing high quality guidelines
Strength of recommendation: strong
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3.2.3. What is the role of rapid diagnostic tests and point of care tests in HCV screening?
A rapid diagnostic test (RDT) is a test which provides a result in a short time period, typically less than 30 
minutes. The term is typically used to describe rapid tests performed at the point of care (PoC) i.e. in the 
immediate vicinity of a patient, and commonly also called PoC tests (PoCT).
The advantages of RDTs/PoCTs are that they can be used in the community and therefore may lead to 
greater access to testing. The rapid result can facilitate patient management and improve linkage to 
care. WHO has recommended the use of RDTs in settings where there is limited access to laboratory 
infrastructure and testing and/or in populations where access to rapid testing would facilitate linkage to 
care and treatment (52).
In a systematic review and meta-analysis evaluating RDTs/PoCTs pooled accuracy was high overall.
In a systematic review on the effect of RDTs/PoCTs on increasing uptake of screening or improving the 
detection of HCV infection, no studies that contained quantitative data on the frequency of testing and/
or new diagnoses after the introduction of RDTs/PoCTs were identified (131). A number of qualitative 
studies have suggested positive attitudes to RDTs/PoCTs amongst providers and patients (133-136).
Currently available RDTs/PoCTs only test for anti-HCV, meaning traditional venepuncture and laboratory 
based diagnostics will still be required to test for HCV-Ag or HCV-RNA to confirm current infection. 
Therefore it is recommended where possible to screen using a plasma or serum sample to enable a more 
complete diagnosis be made.
Where concerns exist about loss to follow-up, RDTs/PoCTs using finger-prick or DBS specimens can be 
considered. Any RDTs/PoCTs programme should follow the recommendations set out in Guidelines for 
Safe and Effective Management and Use of Point of Care Testing in Primary and Community Care (137). 
 
Recommendation 25
25.1. Where concerns exist about hard-to-reach populations or linkage-to-care then consideration 
could be given to using approved (e.g. CE marked) rapid diagnostic tests tests/point of care tests 
(RDTs/PoCTs) on blood specimens.
25.2. If RDTs/PoCTs are introduced into standard clinical practice then a quality assurance programme 
should be established that addresses internal quality control and external quality assurance. 
Quality/level of evidence: low
Strength of recommendation: conditional/weak
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3.2.4. Screening for other bloodborne viruses
It was not within the scope of this guideline to make recommendations on the need for screening for 
other bloodborne viruses (BBVs).
At present, national guidelines on screening for other BBVs do not exist. Guidelines on HIV testing are in 
development.
Some risk groups for whom HCV screening is recommended may also be at risk for other BBVs, in 
particular PWID, migrants from endemic countries, and MSM.
When offering screening for HCV, consideration should be given to the need for screening for other BBVs 
also.
Recommendation 26
26.1. When offering screening for HCV, consideration should be given to the need for screening for 
other BBVs also.
Quality/level of evidence: low
Strength of recommendation: strong
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3.3. Interventions to increase uptake of HCV screening and subsequent 
linkage to care
A key requirement for Ireland to meet its goal of elimination by 2030 is for undiagnosed cases to be 
detected through screening and subsequently linked to care and treatment. Those most at risk of HCV are 
often from marginalised groups of society and may experience barriers to accessing healthcare services 
such as screening.
Interventions which have been shown to have a positive impact on the uptake of screening amongst high 
risk groups include targeted case finding in primary care, support and training for primary care practitioners, 
offering alternative testing and provision of outreach testing (138). Delivery of services in non-specialist 
community settings have, in particular been found to be effective. Targeted HCV testing interventions have 
been shown to be more effective compared to no targeted interventions, or routine practice, in increasing 
the number of people tested, anti-HCV cases detected, referrals to a specialist, attendance at a specialist, 
and cases commencing treatment (139). Practitioner based targeted testing interventions (i.e. where a 
health or social care professional was given support to offer risk assessment and/or testing) were found to 
be most effective.
Recommended settings for testing include: mobile clinics, community settings, harm reduction programmes 
or low threshold service centres visited by PWID, correctional settings, primary care settings (118, 140). 
NICE determined that while pilot studies of community pharmacy testing in the UK have shown good 
acceptability and detection rates, there was not yet sufficient evidence to uniformly support community 
pharmacy testing (86, 141, 142).
A number of studies have showed improvements in referrals to specialist care and attendance with the use 
of care co-ordinators, patient navigators, or peer driven interventions (143-151).
Value judgement
There are a number of initiatives already underway in Ireland employing such strategies (see Appendix 12 
of the full guideline). Such initiatives should be supported and evaluated to inform the best way to improve 
uptake and linkage to care in the Irish setting.
While the scope of this guideline is limited to screening, it is recognised that in order to achieve the 
goal of elimination by 2030, action is required across the entire continuum of HCV care. A national HCV 
programme with a mandate and resources to co-ordinate actions across the entire continuum of care 
should be established as recommended by WHO. 
Recommendation 27
27.1. Interventions to increase uptake of screening and linkage to care, particularly amongst vulnerable 
groups, should be supported and evaluated. 
27.2. A national HCV programme with a mandate spanning the entire HCV continuum of care to include 
full implementation of the National Hepatitis C Strategy and the National Hepatitis C Treatment 
Programme (HSE NHCTP) should be established.
Quality/level of evidence: low
Strength of recommendation: strong
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4 Good practice points for healthcare professionals involved in HCV screening
Healthcare professionals should consider the following points: 
• Any contact with services provides an opportunity to offer HCV screening to those at risk (see 
Appendix 1 for a list of risk populations). 
• HCWs should be cognisant that a person may fall into a potential risk group for HCV unrelated to 
their reason for presentation to a health service.
• HCWs should be cognisant that a person may have more than one risk factor for HCV and this should 
be considered when determining the need for repeat testing e.g. a migrant from an intermediate 
or high prevalence country may warrant repeat screening rather than one-off screening due to also 
being a current PWID.
• HCV testing should be considered in those with an unexplained rise in ALT.
• Screening should be undertaken voluntarily*.
• While offering HCV screening, HCWs should counsel on the testing process, the process of receiving 
results, and the importance of returning for test results.
• Confidentiality should be maintained during the offer of screening and delivery of results.
• An offer of a test or a negative test result provides an opportunity to counsel about prevention and 
harm reduction.
• Upon a diagnosis of HCV infection newly diagnosed persons should be:
o Referred for specialist assessment (further details available at: http://www.hse.ie/eng/health/
az/H/Hepatitis-C/Treating-hepatitis-C.html). Community based assessment and treatment 
models are being piloted and may be more widely available in the future. 
o Informed of the next steps, in terms of subsequent diagnostic tests required, and treatment 
options.
o Provided with information on HCV, including how to reduce the risk of transmission to others.
o Counselled on the importance of linkage to care.
o Directed to services which can provide support and counselling as needed (see Appendix 12 
of the full guideline).
• Continuity of care should be maintained as a patient transitions between services, settings, or 
circumstances (e.g. prison to community, homelessness to home)
*In certain circumstances screening is mandated by legislation (i.e. donors of substances of human 
origin). In other circumstances, failure to agree to screening may prohibit a person from undertaking 
certain activities in order to maintain patient safety (e.g. healthcare workers will be prohibited from 
performing exposure prone procedures).
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5 Appendices
Only appendices 1, 2, 5 and 15 are presented here as they are key to interpretation of the recommendations 
presented in this Summary Guideline.
Please refer to the full guideline report for the following appendices.
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Appendix 1: Risk populations for HCV
Risk populations for HCV to guide screening decisions:
• Those who have ever injected drugs 
• Those who have used unprescribed or illicit drugs by a route other 
than injecting (non-injecting drug use (NIDU)), if there is a possibility of 
transmission of infection by the route of administration
• Prisoners or former prisoners
• Homeless people who have a history of engaging in risk behaviours 
associated with HCV transmission, or who have had a potential HCV risk 
exposure
• Migrants from a country with an intermediate and high prevalence of 
HCV (anti-HCV ≥ 2%*) 
• People who are HIV positive
• Infants of HCV-RNA positive women
• Men who have sex with men
• People on renal dialysis or who have had a kidney transplant
• Recipients of blood or blood components in Ireland prior to October 
1991 who have not yet been tested
• Recipients of anti-D immunoglobulin in Ireland between 1st May 1977 
and the end of July 1979, and 1st March 1991 to 18th February 1994 who 
have not yet been tested 
• Recipients of plasma derived clotting factor concentrates in Ireland prior 
to 1992 who have not yet been tested
Strong 
recommendation 
– Screening 
should be offered
• Those with a tattoo, particularly those who received tattoos a number of 
decades ago, in non-professional settings, prisons, countries with a high 
prevalence of HCV, or in circumstances where infection control was poor 
• Household contacts of a person who is HCV positive in circumstances 
where household transmission is more likely to have occurred 
• Recipients of solid organ transplants in Ireland prior to the introduction 
of routine screening
• Recipients of blood components and blood products overseas in any 
country where a quality assured blood donor screening programme may 
not have been in place 
• People who have received medical or dental treatment in countries 
where HCV is common (anti-HCV prevalence ≥ 2%*) and infection control 
may be poor 
• Sexual partners of known HCV cases: 
o If the case or contact is also HIV positive
o If the HCV-infected case is an injecting drug user 
• Sexual contacts of persons who inject drugs, but where HCV status is 
unknown or where there is evidence of resolved infection
• Commercial sex workers
Weak 
recommendation 
– Screening 
should be 
considered
* A list of countries this includes is available in Appendix 2.
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Appendix 2: Hepatitis C endemic countries
Table A 1 lists the countries known to have a prevalence of anti-HCV ≥2%.
Table A 1: Anti-HCV prevalence of countries with a prevalence ≥ 2%
Country Anti-HCV 
prevalence
Country Anti-HCV 
prevalence
Albania 2.4 Kyrgyzstan 2.5
Angola 4.2 Latvia 2.4
Armenia 5.4 Lebanon 3.1
Azerbaijan 3.1 Liberia 5.3
Bahrain 3.1 Lithuania 2.9
Benin 3.6 Mali 5.3
Burkina Faso 5.3 Republic of Moldova 4.5
Cambodia 2.3 Mongolia 10.8
Cameroon 11.6 Niger 5.3
Cape Verde 5.3 Nigeria 8.4
Central African Republic 4.2 Oman 3.1
Chad 5.3 Pakistan 5
Congo 4.2 Palestinian Territory, Occupied 3.1
Congo, the Democratic Republic of the 4.3 Puerto Rico 2.3
Côte d’Ivoire 3.3 Romania 3.2
Egypt 15.7 Russian Federation 4.1
Equatorial Guinea 4.2 Sao Tome and Principe 5.3
Estonia 3.3 Senegal 5.3
Gabon 11.2 Sierra Leone 5.3
Gambia 2.1 Syrian Arab Republic 3.1
Georgia 6.7 Taiwan, Province of China 4.4
Ghana 5.3 Tajikistan 3.1
Guinea 5.3 Thailand 2.7
Guinea-Bissau 5.3 Togo 5.3
Iraq 3.2 Turkmenistan 5.6
Italy 4.4 Ukraine 3.6
Ivory Coast 5.3 United Arab Emirates 3.1
Jordan 3.1 Uzbekistan 11.3
Kazakhstan 3.3 Western Sahara 3.1
Kuwait 3.1 Yemen 2.2
(Source: adapted from “Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA” by 
European Centre for Disease Prevention and Control. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.
eu/en/publications/Publications/epidemiological-assessment-hepatitis-B-and-C-among-migrants-EU-EEA.pdf (55))
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Appendix 3: Recommendations from the National Hepatitis C Strategy 
2011-2014
Table A 2: Recommendations relevant to screening from the National Hepatitis C Strategy 2011-2014
Recommendation 23a Provide ready access for GPs and other community healthcare providers to 
diagnostic facilities.
Recommendation 24b Provide every prisoner on committal with a hepatitis C risk assessment, 
including details of previous virological tests, and offer screening for blood-
borne viruses, including hepatitis C, if required.
Recommendation 26 Establish guidelines with regard to hepatitis C screening of individuals from 
endemic countries/ new entrants to the Irish healthcare system.
Recommendation 27a Continue targeted antenatal screening for those with risk factors for hepatitis C 
infection.
Recommendation 27b Regular review of the evidence with regard to universal antenatal screening.
Recommendation 28 Offer and promote screening for hepatitis C and other blood-borne diseases 
to those who attend services such as Needle-Exchange programmes and other 
harm-reduction services.
Recommendation 29b Develop standard protocols for testing, diagnosis, evaluation, referral for 
treatment, monitoring of treatment and monitoring of patients not on 
treatment.
Source: Adapted from “National Hepatitis C Strategy 2011-2014”. By Health Service Executive. Dublin: HSE; 2012. 
Available from: https://www.hse.ie/eng/services/Publications/HealthProtection/HepCstrategy.pdf (10)
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Appendix 5: Key questions
The following is a list of key questions which are to be addressed by the guideline:
1. Is screening for hepatitis C beneficial? 
a. For the individual?
b. For society?
2. Who should be offered screening for hepatitis C?
a. Who is at risk for hepatitis C infection?
b. Should the following specified groups be offered screened:
i. Migrants
ii. Prisoners
iii. People who currently use or have a history of unprescribed or illicit drug use 
iv. Sexual contacts of PWID
v. Pregnant women
vi. Men who have sex with men
vii. People who are homeless 
viii. Healthcare workers
ix. People having an STI screen/ test
x. Those engaging in, or with a history of, high risk sexual behaviour
xi. People on renal dialysis or who have had renal dialysis in the past
xii. Recipients of unscreened blood and blood products in Ireland (donated pre October 1991) 
who have not been previously screened
xiii. Recipients of tattoos and body piercings
xiv. Those who received medical treatment in high prevalence countries
c. Should the following contacts of known cases of hepatitis C be screened:
i. Sexual contacts
ii. Household contacts
iii. Children of infected mothers
d. Any other group identified from 2.a
e. Should there be screening of the general population?
f. Is there a role for birth cohort screening?
3. What screening of blood, tissue or organ donations, or donors should be undertaken?
4. How should screening be implemented for each group for which screening is recommended, 
including:
a. Should screening be universal or selective?
b. What settings should screening be offered in?
c. What specimen type should be used?
d. What test should be used?
e. What is the role for point-of-care tests?
f. What should the screening sequence process be?
g. How frequently should those who remain at risk be screened?
5. For those being screened for hepatitis C – should they be screened for other bloodborne infections 
at the same time?
6. How can those at risk be communicated with and encouraged to take up screening?
7. How can those identified as being infected through screening be linked into care?
8. What are the economic implications of screening? 
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Appendix 15: Glossary of terms and abbreviations
Definitions within the context of this document
Acute infection HCV infection is classified as acute if detected within six months after 
exposure. Determination of infection as acute is difficult unless a person 
has had a recent negative test.
Anti-HCV antibody Antibody to HCV, which can be detected in the blood usually within two 
or three months of HCV infection or exposure. 
Anti-HCV antibody positive Being anti-HCV positive indicates that a person has been infected with 
HCV at some stage. However, infection may have resolved spontaneously 
or due to treatment. Further testing is required to establish if the person 
is currently infected.
Chronic infection Persistence of HCV-RNA for at least six months after infection. 
Cirrhosis An advanced stage of liver disease characterised by extensive hepatic 
fibrosis, nodularity of the liver, alteration of liver architecture and 
disrupted hepatic circulation. 
Chemsex  The use of recreational drugs for or during sex. 
Endemic The constant presence of a disease or infectious agent within a given 
geographic area or population group; may also refer to the usual 
prevalence of a given disease within such area or group. 
Enzyme immunoassay (EIA) Laboratory-based serological immunoassays that detect antibodies, 
antigens, or a combination of both.
Exposure incident A specific exposure to the eye, mouth, other mucous membrane, 
non-intact skin, or parenteral exposure to blood or other potentially 
infectious materials. 
Exposure prone procedures These include procedures where the worker’s hands may be in contact 
with sharp instruments, needle tips or sharp tissues (e.g. spicules of 
bone or teeth) inside a patient’s open body cavity, wound or confined 
anatomical space where the hands or fingertips may not be completely 
visible at all times. There is a risk that injury to the worker may result in 
the exposure of the patient’s open tissues to the blood of the worker. 
They have been more precisely defined as procedures which involve 
surgical entry into tissues, cavities or organs or repair of major traumatic 
injuries, vaginal or Caesarean deliveries or other obstetric procedures 
during which sharp instruments are used; the manipulation, cutting 
or removal of any oral or perioral tissues including tooth structure, 
during which bleeding may occur. EPPs would not usually include giving 
injections, taking blood, setting up IV lines, minor surface suturing, 
and the incision of abscesses, routine vaginal or rectal examinations or 
uncomplicated endoscopies (114).
HCV-Ag HCV core antigen which is released into plasma can be detected from 
early on and throughout the course of infection.
HCV-RNA HCV viral genomes that can be detected and quantified in serum by 
nucleic acid testing (NAT). 
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HCV-RNA positive/ viraemic/ 
current infection
A person is HCV-RNA positive when virus is detectable in their 
circulation. This is also referred to as being viraemic or having current or 
active infection. While viraemic, a person is infectious, although the risk 
of transmitting infection is related to the viral load. 
Hepatocellular carcinoma 
(HCC)
Primary cancer of the liver arising from the hepatocytes. 
Incidence The number of new cases of a disease that develop in a given period of 
time.
Men who have sex with men 
(MSM) 
Any male who engages in sexual activity with a male regardless of sexual 
identity or sexual desire.
Migrant The term ‘migrant’ is taken to include any person who was not born 
in Ireland but who is currently living here temporarily or permanently. 
This includes: all persons who have migrated to this country voluntarily 
for whatever reason, including migrant workers and foreign students; 
international adoptees; those who have been compelled to leave their 
original country of nationality or residence for whatever reason and 
have come to this state to seek its protection as asylum seekers or 
refugees; undocumented or irregular migrants including those who are 
trafficked.
Multiplex or multidisease 
testing 
Refers to testing using one specimen in the same test device (or reagent 
cartridge) that can detect other infections (e.g. HIV, syphilis, HCV, HBV).
Predictive value The probability that a person’s test result truly reflects their infection/
disease status. Negative predictive value (NPV) is the probability that 
when a person’s test result is negative, they truly do not have the 
infection/disease. Positive predictive value (PPV) is the probability that 
when a person’s test result is positive, they truly do have the infection/
disease. Predictive values are influenced by the prevalence of the 
disease in the population. 
Nucleic acid testing (NAT) A molecular technology, for example, polymerase chain reaction or 
nucleic acid sequence-based amplification that can detect very small 
quantities of viral nucleic acid (RNA or DNA), either qualitatively or 
quantitatively.
Parenteral Piercing the skin barrier or mucous membranes e.g. by needlestick. 
Percutaneous An exposure through the skin (e.g. a needlestick or cut with a sharp 
object) or contact of non-intact skin (e.g. exposed skin that is chapped, 
abraded, or afflicted with dermatitis) with blood, tissue, or other body 
fluids that are potentially infectious. 
Point of care test (PoCT) A test performed in the immediate vicinity of a patient to provide a rapid 
result outside the conventional laboratory environment 
Post-exposure prophylaxis 
(PEP)
The administration of a drug to prevent the development of an infection 
after the patient has been exposed to the infection. 
Pre-exposure prophylaxis 
(PrEP)
The administration of a drug to prevent the development of an infection 
before the patient has been exposed to the infection. 
Prevalence The proportion of individuals in a population having a disease at a given 
time.
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Rapid diagnostic test (RDT) A test which provides a result in a short time period, typically less than 
30 minutes. While laboratories do undertake some RDTs, the term is 
typically used to describe rapid tests performed at the point of care
Risk factors An aspect of personal behaviour or lifestyle, an environmental exposure, 
or an inborn or inherited characteristic that is associated with an 
increased occurrence of disease.
Sensitivity of a test The ability of a test to correctly identify those with the infection or 
disease (i.e. true positives/true positives + false negatives).
Serological assays Assays that detect the presence of either antigens or antibodies. 
Seroprevalence The level of a pathogen in a population, as measured in blood serum. 
Sharps Any items that have the potential to puncture the skin and inoculate the 
recipient with infectious material. 
Substances of human origin 
(SoHO) 
Includes blood and blood products, organs, tissues, and cells, including 
reproductive cells and human embryonic stem cells.
Specificity of a test The ability of a test to correctly identify those without the infection or 
disease (i.e. true negatives/true negatives + false positives).
Sustained virologial response 
(SVR)
Undetectable HCV-RNA in blood by 12 weeks (SVR12) and/or 24 weeks 
(SVR24) after the end of treatment. 
Vertical transmission Vertical transmission or mother-to-child transmission of an infectious 
disease is when infection passes from an infected mother to her infant. 
This can occur in utero, during delivery, or through breastfeeding.
Viral load Viral load relates to the amount of HCV virus which is detectable in a 
person’s blood.
Window period The time interval after infection during which serological assays for 
antigen and/or antibody are negative.
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Abbreviations
The following abbreviations are used in this document:
AAP American Academy of Pediatrics
AASLD American Association for the Study of Liver Disease
Ab Antibody
Ag Antigen
AIDS Acquired immunodeficiency syndrome
ALT Alanine aminotransferase
Anti-HCV Antibody to hepatitis C virus
ARR Absolute risk reduction
BASHH British Association of Sexual Health and HIV 
BBV Bloodborne virus
CAG Clinical Advisory Group (referring to the CAG of the NHCTP)
CDC Centers for Disease Control and Prevention
CE Conformité Européene
CER Cost-effectiveness ratio
CI Confidence Interval
CIDR Computerised infectious disease reporting system
CUA Cost utility analysis
DAA Direct acting antiviral agents
DBS Dried blood spot
DoH Department of Health
EASL European Association for the Study of the Liver
ECDC European Centre for Disease Prevention and Control
EEA European economic area
EIA Enzyme immunoassay
ELCS Elective Caesarean Section
ELISA Enzyme linked immunoassay
ELPA European Liver Patients Association
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EPHN European Paediatric Hepatitis C Virus Network
EPP Exposure prone procedure
ERHA Eastern Regional Health Authority
ESLD End stage liver disease
ETB Education and Training Board
ETHOS European Typology of Homelessness and Housing Exclusion
ETR End of treatment response
EU European Union
FEANTSA European Federation of National Organisations Working with the Homeless
FDA Food and Drug Administration, USA
GDG Guideline Development Group
GI Gastrointestinal
GMHS Gay Men’s Health Service
GMS General Medical Services
GP General Practitioner
GRADE Grading of Recommendations Assessment, Development and Evaluation
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GUM Genitourinary medicine
HCC Hepatocellular carcinoma
HBV Hepatitis B virus
HCV Hepatitis C virus
HCV-RNA Hepatitis C virus ribonucleic acid
HCW Healthcare worker
HIPE Hospital Inpatient Enquiry System
HIQA Health Information and Quality Authority
HIV Human immunodeficiency virus
HPRA Health Products Regulatory Authority
HPSC Health Protection Surveillance Centre
HRB Health Research Board
HSE Health Service Executive
HTA Health technology assessment
IBTS Irish Blood Transfusion Service
ICER Incremental cost-effectiveness ratio
ICGP Irish College of General Practitioners
IDU Injecting drug use
IDSI Infectious Disease Society of Ireland
IFN Interferon
IKA Irish Kidney Association
INAB Irish National Accreditation Board 
INF Interferon
IPS Irish Prison Service
IQR Interquartile range
ISCM Irish Society of Clinical Microbiologists
IUSTI International Union against Sexually Transmitted Infections 
JPAC Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional 
Advisory Committee
LGV Lymphogranuloma venereum
LFTs Liver function tests
MedLIS National Medical Laboratory Information System 
MISI Men who have sex with men Internet Survey Ireland
MN-CMS Maternal and Newborn Clinical Management System 
MSM Men who have sex with men
NASPHGN North Amercian Society for Pediatric Hepatology, Gastroenterology and Nutrition 
NAT Nucleic acid testing
NCEC National Clinical Effectiveness Committee
NCPE National Centre for Pharmacoeconomics
NGO Non-governmental organisation 
NHCTP National Hepatitis C Treatment Programme
NICE National Institute for Health and Care Excellence (formerly National Institute for Clinical 
Excellence, and National Insitute for Health and Clinical Excellence)
NIDU Non-injecting drug use
NPSO National Patient Safety Office
NPV Negative predictive value
NUIG National University of Ireland, Galway
NVRL National Virus Reference Laboratory
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ODTI Organ Donation and Transplant Ireland
OR Odds Ratio
OST Opioid substitution therapy
PAG Programme Advisory Group (referring to the PAG of the NHCTP)
PCR Polymerase chain reaction
PEP Post-exposure prophylaxis
PI Protease inhibitor
PICO Patient, intervention, comparator, outcome
PNE Patient notification exercise
PoC Point of care
PPV Positive predictive value
PrEP Pre-exposure prophylaxis
PWID People who injects drugs
PY Person years
QALY Quality adjusted life year
RBV Ribavirin
RCPI Royal College of Physicians of Ireland 
RCSI Royal College of Surgeons in Ireland
RCT Randomised controlled trial
RDT Rapid diagnostic test
RIBA Recombinant immunoblot assay
RNA Ribonucleic acid
ROD Rigour of Development
RR Relative risk
RTU Recipient Tracing Unit
SaBTO Safety of Blood Tissues and Organs (refers to the UK’s Advisory Committee on the Safety of Blood 
Tissues and Organs)
SHEA Society for Healthcare Epidemiology of America
SI Statutory Instrument
SIGN Scottish Intercollegiate Guidelines Network
SoHO Substances of human origin
SSSTDI Society for the Study of Sexually Transmitted Diseases in Ireland
STI Sexually transmitted infection
SVR Sustained virological response
TasP Treatment as prevention
UISCE Union for Improved Services Communication and Training
UK United Kingdom
UNHCR United Nations High Commissioner for Refugees (also known as the UN Refugee Agency)
USA United States of America
USPSTF United States Preventive Services Taskforce
WHA World Health Assembly
WHO World Health Organization
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